Project Grant R01AI195422
Award Date
7/21/25
Completion Date
6/30/29
Dollars Obligated
$3.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,332,155 to Emory University to conduct research focused on developing immunotherapies to cure HIV in SHIV-infected infant macaques. The key objectives are to evaluate strategies that leverage broadly neutralizing antibodies (bNAbs) in combination with virus reactivation, innate immune stimulation, and attachment...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $862,398 to the Fred Hutchinson Cancer Center in Seattle, WA over a 5-year period starting on August 1, 2025. The goal of this project is to develop novel chimeric antigen receptor (CAR) T-cell therapies that can selectively target and deplete the PD-1+ HIV/SIV reservoir in non-human primate models. The research aims to advance understanding of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, aims to understand the reservoir effects and curative potential of a CD3/CCR5 bispecific antibody (BSAB) in treating HIV infection in infant macaques. The $1,420,190 award will be used to improve the manufacturing and safety of the BSAB, and rigorously test its mechanisms of action, including its ability to deplete the HIV reservoir and...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel multi-epitope protease cleavage sites (MEPCS) vaccine for protecting against SIV (Simian Immunodeficiency Virus) rectal transmission. The $650,156 award, effective August 21, 2024 through June 30, 2029, will support comparative evaluations of a cold-chain friendly and long-term stable...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $387,804 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The grant, awarded on August 6, 2024, will fund a research project to investigate the impact of estrogen replacement therapy on bone health in an aging population of women living with HIV. The project aims to measure the effects of antiretroviral therapy (ART) and menopause,...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...